Abstract：
Targeted cancer therapy (TCT) is gaining increased interest because it reduces the risks of adverse side effects by specifically treating tumor cells. TCT testing has traditionally been performed using two-dimensional (2D) cell culture and animal studies. Organ-on-a-chip (OoC) platforms have been developed to recapitulate cancer in vitro, as cancer-on-a-chip (CoC), and used for chemotherapeutics development and testing. This review explores the use of CoCs to both develop and test TCTs, with a focus on three main aspects, the use of CoCs to identify target biomarkers for TCT development, the use of CoCs to test free, un-encapsulated TCTs, and the use of CoCs to test encapsulated TCTs. Despite current challenges such as system scaling, and testing externally triggered TCTs, TCToC shows a promising future to serve as a supportive, pre-clinical platform to expedite TCT development and bench-to-bedside translation.
摘要：
靶向癌症治疗（TCT）正在获得越来越多的兴趣，因为它通过特异性治疗肿瘤细胞降低了不良副作用的风险。传统上使用二维(2D)细胞培养和动物研究进行TCT测试。已经开发了芯片上器官（OoC）平台来概括体外癌症，作为芯片上的癌症(CoC)，并用于化学疗法的开发和测试。这篇综述探讨了使用CoC来开发和测试TCT，重点是三个主要方面，使用CoC识别TCT开发的目标生物标志物，使用CoC免费测试，未封装的TCT，以及使用CoC测试封装的TCT。尽管当前面临系统扩展等挑战，并测试外部触发的TCT，TCToC显示了一个充满希望的未来，临床前平台，以加快TCT的开发和工作台到床边的翻译。
